TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05565521

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose escalation + Reduced Margin Adaptive Radiotherapy
Description: Concurrent chemoradiation with temozolomide (TMZ) over 3 weeks (40 Gy in 15 fractions). The gross tumor volume (GTV) plus margin will be boosted simultaneously (SIB) to 52.5 Gy in 15 fractions. Radiation will be delivered on the MR-Linac with a reduced clinical target volume (CTV) margin of minimum 5 mm and a weekly online adaptive approach.
Study: NCT06613698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4532990
Description: GSK4532990 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4532990
Description: GSK4532990 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4532990
Description: GSK4532990 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4532990
Description: GSK4532990 will be administered
Study: NCT05754996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin 550Mg Tab
Description: Rifaximin 550 MG twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin 550Mg Tab
Description: Rifaximin 550 MG twice daily
Study: NCT06074497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KGX101- Cohort -1
Description: Single dose of 0.1, 0.3, 1μg/kg of KGX101 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KGX101- Cohort 1
Description: Single dose of 0.3, 1.0, 3.0μg/kg of KGX101 every 3 weeks
Study: NCT05296733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: BI 456906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: BI 456906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: BI 456906
Study: NCT06613698

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered
Study: NCT06613945

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP biliary drainage
Description: bilateral metallic stents insertion will be attempted through ERCP to secure biliary drainage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined ERCP and EUS-HGS biliary drainage
Description: unilateral metallic stent will be inserted on right side by ERCP and a hepaticogastrostomy transmural stent will be inserted on left side by EUS to secure biliary drainage.
Study: NCT05854992

Intervention type: DRUG
Intervention: Acute migraine treatment with any prescribed triptans
Description: Sumatriptan, treximet (sumatriptan/naproxen combination), zolmitriptan, naratriptan, rizatriptan, almotriptan, eletriptan, and frovatriptan. No restriction on dose, frequency, duration, or delivery routes.
Study: NCT05296733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: BI 456906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: BI 456906
Study: NCT06173934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin injection 15 minutes before meals
Description: Adjust insulin injection time to observe blood glucose spectrum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin injection 15 minutes after eating
Description: Adjust insulin injection time to observe blood glucose spectrum
Study: NCT05053711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS+rPMS_iTBS_M
Description: Repetitive peripheral magnetic stimulation (rPMS) intermittent theta-burst stimulation pattern (iTBS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times at median nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
Study: NCT02371096

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MabThera (rituximab)
Study: NCT05053711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS+rPMS_cTBS_M
Description: Repetitive peripheral magnetic stimulation (rPMS) continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times at median nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS+sham rPMS_M
Description: Repetitive peripheral magnetic stimulation (rPMS) sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds at median nerve on the affected hand(almost no pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds on affected hemisphere(almost no pulse: 1200 pulses in total).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS+rPMS_iTBS_U
Description: Repetitive peripheral magnetic stimulation (rPMS) intermittent theta-burst stimulation pattern (iTBS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times at ulnaris nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS+rPMS_cTBS_U
Description: Repetitive peripheral magnetic stimulation (rPMS) continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times at ulnar nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS+sham rPMS_U
Description: Repetitive peripheral magnetic stimulation (rPMS) sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds at ulnar nerve on the affected hand(almost no pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds on affected hemisphere(almost no pulse: 1200 pulses in total).
Study: NCT05469932

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Rexon device
Description: Rexon device for 20 minutes each session. A total of 4 sessions with one week apart from each other.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rexon device
Description: Rexon device for 20 minutes each session. A total of 4 sessions with one week apart from each other.
Study: NCT05438784

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: orbital bone reconstruction with patient specific titanium implant
Description: orbital defects reconstruction will be virtually planned by software and a patient specific titanium implant will be manufactured using milling technique depending on CAD-CAM technology

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: orbital bone reconstruction with preformed titanium plate preoperatively bended on stereolithographic model
Description: orbital defects reconstruction will be virtually planned by software and a reconstructed stereolithographic model will be 3D printed and used for preoperatively bending of preformed titanium implant.
Study: NCT02371096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGB-03
Study: NCT06074497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KGX101- Cohort 2
Description: Single dose of 1, 1 and 3μg/kg of KGX101 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KGX101- Cohort 3
Description: Single dose of 1,3 and 6μg/kg of KGX101 every 3 weeks
Study: NCT05139082

Intervention type: DRUG
Group type: OTHER
Intervention: TQB3616 capsules＋ TQB2450 injection
Description: TQB3616 is a highly active CDK4/6 inhibitor. Preclinical studies have shown that it has a strong inhibitory effect on the kinase activity of CDK4/6.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors.
Study: NCT05515471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR8058 eye drops
Description: SHR8058 eye drops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline eye drops.
Description: saline eye drops.
Study: NCT05290792

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Administration of FluMist (Live Attenuated Influenza Vaccine)
Description: Participants will received the intranasal FluMist vaccine that will serve as a proxy for a viral respiratory tract infection and trigger a mild immune response.
Study: NCT06557486

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress reduction
Description: Participants assigned to the 8-week mindfulness program attended weekly 120-150 minute in-person group sessions for the entire duration. In these sessions, the instructor progressively will introduce and guide formal mindfulness practices while facilitating the sharing of experiences.
Study: NCT05482542

Intervention type: OTHER
Group type: OTHER
Intervention: Autologous hematopoietic stem cell transplantation
Description: Autologous hematopoietic stem cell transplantation

Intervention type: OTHER
Group type: OTHER
Intervention: Autologous hematopoietic stem cell transplantation
Description: Autologous hematopoietic stem cell transplantation

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide/ATG
Description: Cyclophosphamide/ATG

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide/Rituximab
Description: Cyclophosphamide/Rituximab
Study: NCT05854992

Intervention type: DRUG
Intervention: Standard of care management of acute migraine without triptans
Description: Any standard of care management without triptans

Intervention type: DRUG
Intervention: Standard of care management of acute migraine without triptans
Description: Any standard of care management without triptans
Study: NCT06622031

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt
Description: A needle punctured the portal vein through the transjugular approach. After a successful puncture, the parenchymal tract was dilated, and covered stents were introduced. The specifications of the covered stents were 8 mm × 50 mm, 8 mm × 60 mm, 8 mm × 70 mm, and 8 mm × 80 mm. All of the diameters of the bare stents were 8 mm, and the lengths were 50-80 mm. The portal vein pressure was measured before and after shunt creation. After the insertion of TIPS, all of the participants received a diuretic treatment and a salt-limited diet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg
Study: NCT02080910

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Study: NCT05107427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRx0518
Description: MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is one capsule two times per day for the duration of the treatment period.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avelumab 20 mg/mL Intravenous Solution (IV)
Description: Avelumab is an IV administered monoclonal antibody that blocks the interaction of programmed death ligand-1 (PD-L1) with its receptors PD-1 and B7.1 on T cells and antigen-presenting cells, and has been shown to activate adaptive and innate immune functions.~The study dosing regimen is 800 mg (four 20mL vials of 20mg/mL solution) for IV infusion once every two weeks
Study: NCT06428682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Experimental group will receive TXA intraoperatively (15mg/kg IV, once at beginning of case then re dose at 4hrs if operation goes longer) at the time of their surgery.
Study: NCT06622031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Tislelizumab (200mg intravenously every 3 weeks), Sintilimab (200mg intravenously every 3 weeks), Camrelizumab (200mg intravenously every 3 weeks)
Study: NCT06428682

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control group will receive same volume equivalent of saline intravenously at the time of their surgery.
Study: NCT06074497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KGX101- Cohort 4
Description: Single dose of 1,3,12μg/kg of KGX101 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KGX101- Cohort 5
Description: Single dose of 2, 5 and 15 μg/kg of KGX101 every 3 weeks
Study: NCT05464550

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye tracker
Description: Eye movements on a screen are captured with an eye tracker during a repeated measures before/after a directed autobiographical recall.
Study: NCT06614257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LG-TAP block with local anesthetic
Description: The laparoscopic guided TAP Block was performed by surgeon at the beginning of surgery, injecting 15 ml of Ropivacaine 0.5% on each side, using an atraumatic needle (10/15 cm length, 20 Gauge diameter) close to the anterior axillary line, between the iliac crest and the subcostal margin. Correct needle tip positioning between the transverse muscle of the abdomen and the internal oblique was verified through laparoscopic guidance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Port site infiltration
Description: Prior the surgical incision, an infiltration of the laparoscopic access using a total of 10 ml Ropivacaine 0.5% was performed by surgeon

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Port site infiltration
Description: Prior the surgical incision, an infiltration of the laparoscopic access using a total of 10 ml Ropivacaine 0.5% was performed by surgeon

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LG-TAP block with saline solution
Description: The laparoscopic guided TAP Block was performed by surgeon at the beginning of surgery, injecting 15 ml of Saline solution (NaCl 0.9%) on each side, using an atraumatic needle (10/15 cm length, 20 Gauge diameter) close to the anterior axillary line, between the iliac crest and the subcostal margin. Correct needle tip positioning between the transverse muscle of the abdomen and the internal oblique was verified through laparoscopic guidance.
Study: NCT06389786

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Pelvic Lymph Node Dissection
Description: Undergo bilateral pelvic lymph node dissection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo tissue sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flotufolastat F-18 Gallium
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Radical Prostatectomy with Robotics
Description: Undergo robotic radical prostatectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI or PET/MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/MRI
Study: NCT05129423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTPS9579A
Description: MTPS9579A will be administered.
Study: NCT05239182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9-ING-41
Description: 9-ING-41 is a small molecule potent selective GSK-3β inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Humanized, hinge-stabilized, IgG4κ monoclonal antibody that recognizes human PD-1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: cytotoxic chemotherapy agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: cytotoxic chemotherapy agent
Study: NCT04684511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRM-201 (Rofecoxib)
Description: Eligible patients will be randomized to receive TRM-201 or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT06687668

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short Leg Walking Plaster Cast
Description: A short leg walking plaster cast that extends from the head of the metatarsal to the mid-calf. This cast provides stability to the fracture site while allowing limited weight-bearing, and is designed to restrict inversion and eversion movements, thereby reducing the risk of fracture displacement. Applied for six weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking Foot Plaster Cast
Description: A walking foot plaster cast that covers the foot from the metatarsal heads but leaves the toes exposed. This cast allows weight-bearing while restricting side-to-side movement, providing support to the fracture area without immobilizing the ankle. It will be used for six weeks.
Study: NCT06622499

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Description: On the first trial day healthy volunteers are randomized to receive 1 liter of Ringer's lactate either cold (10°C, 50°F), or at room temperature (22°C, 71.6°F) with 100 ml/min. After a minimum washout period of 24 hours, subjects are switched to receive infusion at the other aforementioned temperatures.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Description: On the first trial day healthy volunteers are randomized to receive 1 liter of Ringer's lactate either cold (10°C, 50°F), or at room temperature (22°C, 71.6°F) with 100 ml/min. After a minimum washout period of 24 hours, subjects are switched to receive infusion at the other aforementioned temperatures.
Study: NCT06696079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early Resumption of Oral Anticoagulation Therapy
Description: The patient's prescribed anticoagulant therapy for atrial fibrillation is resumed on the 5th postoperative day following burr-hole surgery for chronic subdural hematoma. This early resumption strategy is compared to the standard practice of resuming anticoagulation therapy on the 30th postoperative day.
Study: NCT05129423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTPS9579A
Description: MTPS9579A will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTPS9579A
Description: MTPS9579A will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTPS9579A
Description: MTPS9579A will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTPS9579A
Description: MTPS9579A will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched with MTPS9579A will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched with MTPS9579A will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched with MTPS9579A will be administered.
Study: NCT04793698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compassion meditation
Description: 10 week meditation course taught in 90-minute groups

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Applied relaxation
Description: 10 week applied relaxation course taught in 90-minute groups
Study: NCT06274307

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane block
Description: A transversus abdominis plane block (TAP) block using a long-acting local anesthetic is used to manage pain during the intermediate (12-24hr) post-operative period following laparoscopic abdominal surgeries. Drug: The local anesthetic to be used in this specific intervention will be 30 to 40ml of Ropivacaine 0.375%, not to exceed a max dose of 3mg/kg of 0.375% and divided equally bilaterally.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane block
Description: A transversus abdominis plane block (TAP) block using a long-acting local anesthetic is used to manage pain during the intermediate (12-24hr) post-operative period following laparoscopic abdominal surgeries. Drug: The local anesthetic to be used in this specific intervention will be 30 to 40ml of Ropivacaine 0.375%, not to exceed a max dose of 3mg/kg of 0.375% and divided equally bilaterally.
Study: NCT05229978

Intervention type: OTHER
Intervention: Showing an existing Dynamic Consent (computer interface) as prompt
Description: An existing Dynamic Consent interface will be shown as a prompt halfway through the focus group sessions.

Intervention type: OTHER
Intervention: Showing an existing Dynamic Consent (computer interface) as prompt
Description: An existing Dynamic Consent interface will be shown as a prompt halfway through the focus group sessions.

Intervention type: OTHER
Intervention: Showing an existing Dynamic Consent (computer interface) as prompt
Description: An existing Dynamic Consent interface will be shown as a prompt halfway through the focus group sessions.
Study: NCT04840069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluciclovine PET guided Radiotherapy
Description: PET+MRI Based There is no GTV_5400. The GTV_6000 will be defined as the surgical cavity inclusive of any remaining tumor enhancement and the hypermetabolic volume. CTV_5400 will include the GTV_6000 plus a margin of 1.0 cm which may be reduced around natural barriers to tumor growth such as the skull, ventricles, falx, etc. CTV_5400 must also include the entirety of the GTV_6000. There is no CTV_6000. PTV_5400 is the CTV_5400 plus a geometric 3 mm expansion in all dimensions; PTV_6000 is GTV_6000 plus a geometric 3 mm expansion in all dimensions. PTV may extend beyond bony margins and the skin surface. The PTV_5400 must contain the PTV_6000. In the setting of multi-focal disease, the primary target volumes will be defined as above, but for satellite lesions, the GTV_6000 will be defined as any tumor enhancement and hypermetabolic volume. There will be no CTV_6000. PTV_6000 will be defined as GTV_6000 plus a geometric 3 mm expansion in all dimensions.